NASDAQ:ANEB Anebulo Pharmaceuticals Q2 2025 Earnings Report $0.37 -0.01 (-3.16%) As of 09:43 AM Eastern ProfileEarnings HistoryForecast Anebulo Pharmaceuticals EPS ResultsActual EPS-$0.09Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAnebulo Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnebulo Pharmaceuticals Announcement DetailsQuarterQ2 2025Date2/14/2025TimeAfter Market ClosesConference Call DateFriday, February 14, 2025Conference Call Time4:00PM ETUpcoming EarningsAnebulo Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, September 23, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Anebulo Pharmaceuticals Earnings HeadlinesANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc (ANEB) Stock Price, Quote, News & HistoryJuly 1, 2026 | benzinga.comAnebulo’s Selonabant Phase 1 Completion: What Investors Should Watch NextMay 8, 2026 | tipranks.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.July 6 at 1:00 AM | Porter & Company (Ad)Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent UpdatesFebruary 13, 2026 | finance.yahoo.comAnebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plansFebruary 6, 2026 | in.investing.comAnebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SECFebruary 6, 2026 | finance.yahoo.comSee More Anebulo Pharmaceuticals Headlines About Anebulo PharmaceuticalsAnebulo Pharmaceuticals (NASDAQ:ANEB) (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments. The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S. Food and Drug Administration upon completion of these studies. Anebulo has established manufacturing and distribution strategies to support future commercialization, aiming to deliver a differentiated option for patients who require fast-acting, non-oral migraine relief. Founded in 2019 and headquartered in Campbell, California, Anebulo Pharmaceuticals brings together a team of industry veterans in drug delivery and neurology. By leveraging proprietary intranasal delivery technology, the company seeks to address unmet needs in migraine care and expand its development pipeline in related therapeutic areas.View Anebulo Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off? Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
